Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review
- First Online:
In recent years platinum-based chemotherapy has become the standard of care for patients with good performance status after complete resection in stages IB-IIIA non-small-cell lung cancer (NSCLC), although the benefit is mainly in stages II and IIIA.
Patients and methods
In a retrospective trial we evaluate the clinical efficacy and toxicity profile of a platinum-and taxanes-based adjuvant chemotherapy in completely resected IB-IIIA NSCLC. The primary end point was relapse-free survival (RFS); principal secondary end points were overall survival (OS) and safety of the regimen. Potential predictive factors of efficacy and clinical patterns of relapse were also analysed.
From January 2003 to December 2006, 41 patients met the inclusion criteria and were evaluable. Median age at diagnosis was 68.1 years (CI 95% 54–72; range 45–78). Most patients were males (87.7%) and had an Eastern Cooperative Oncology Group performance status score (PS) of 0–1 (87.8%), and 53.6% had adenocarcinomas. Pathological stages were as follow: 48.7% stage IB, 24.3% stage II and 26.8% stage IIIA. 75.6% of patients underwent a lobectomy and mediastinal lymphadenectomy and were treated with a combination of carboplatin AUC6 and paclitaxel 200 mg/m2 (85.36%) for 3 or 4 cycles. With a median follow-up of 18.2 months (range 5.1–46.5), 26 patients (63%) were free of disease and 32 of them were alive (78%). Median RFS was 12.1 months (CI 95% 9.8–14.9) and median OS had not been reached at the time of analysis. Patients with PS ≤1 at diagnosis had a higher RFS [p=0.051 (CI 95% 0.90–0.96)]. Toxicity was generally mild and haematologic events were the most frequent. Non-haematologic toxic effects of chemotherapy were asthenia/anorexia (12.2%), nausea/vomiting (12.2%) and peripheral neuropathy (17%), but severe toxic effects (grade 3 or greater) were uncommon (<10%). We did not observe treatment-related deaths.
Platinum-taxane-based adjuvant chemotherapy in IB-IIIA NSCLC following complete resection is feasible, well tolerated and can be delivered in most patients in the adjuvant setting. Ongoing molecular studies may have value in determining which patients will benefit from adjuvant chemotherapy.
KeywordsNon-small-cell lung cancer Surgical stage Adjuvant chemotherapy Platinum Taxanes
Unable to display preview. Download preview PDF.
- 6.Manser R, Wright G, Hart D et al (2005) Surgery for early stage non-small cell lung cancer. Cochrane Database Syst Rev Jan 25;1:CD 004699Google Scholar
- 10.Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339:1–15, 71–85Google Scholar
- 11.Trimbos JB, Parmar M, Vergote I et al (2003) International Collaborative Ovarian Neoplasm trial 1 and adjuvant chemotherapy in Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 95: 105–112PubMedGoogle Scholar
- 13.Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899–909Google Scholar
- 19.Douillard JY, Rosell R, de Lena M et al (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7:719–727PubMedCrossRefGoogle Scholar
- 20.Pignon JP, Tribodet H, Scagliotti GV et al (2006) Lung Adjuvant Cisplatin Evaluation(LACE): a pooled analysis of 5 randomized trials including 4584 patients. J Clin Oncol 24:366S [Abstract No 7008 2006 ASCO Annual Meeting]Google Scholar
- 23.Nakawava M, Tanaka F, Tsubota N et al; West Japan Study Group for Lung Cancer Surgery (2005) A randomized phase III trial f adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery( WJSG)-the 4th study. Ann Oncol 16:75–80CrossRefGoogle Scholar
- 26.Stewart LA, Burdett S, Tierney JF et al (2007) Surgery and adjuvant chemotherapy (CT) compared to surgery alone in non-small cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomized clinical trials (RCT). J Clin Oncol 25 [Abstract No 7552 2007 ASCO Annual Meeting]Google Scholar
- 27.Strauss GM, Herndon JE, Maddaus MA et al (2004) Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 22:7019Google Scholar
- 28.Strauss GM, Herndon JE, Maddaus MA et al (2006) Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of cancer and leukemia Group B protocol 9633. J Clin Oncol 24 [Abstract-No 7007 2006 ASCO Annual Meeting]Google Scholar
- 32.Bradley JD, Paulus R, Graham MV et al (2005) Phase II of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group-RTOG 9705. J Clin Oncol 23:3480–3487PubMedCrossRefGoogle Scholar
- 37.National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Available at www.nccn.org/professionals/physician_gls/default.asp
- 40.Stephens RJ, Irling DJ, Bleehen NM et al (1996) The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party. Br J Cancer 74:632–639PubMedGoogle Scholar
- 44.The Lung Cancer Study Group (1987) Postoperative T1N0 non-small cell lung cancer. Squamous versus nonsquamous recurrences. J Thorac Cardiovasc Surg 94:349–354Google Scholar
- 54.Rosell R, Jassem M, Skrzypski M et al (2007) Increased BRCA1 mRNA: an independent prognostic variable in completely resected chemo-naïve non-small cell lung cancer (NSCLC) patients (p). [Abstract No. 7551 2007 ASCO Annual Meeting]Google Scholar